CIAO2A
gene geneOn this page
Also known as FLJ22875CIA2A
Summary
CIAO2A (cytosolic iron-sulfur assembly component 2A, HGNC:26235) is a protein-coding gene on chromosome 15q22.31, encoding Cytosolic iron-sulfur assembly component 2A (Q9H5X1). Component of the cytosolic iron-sulfur protein assembly (CIA) complex, a multiprotein complex that mediates the incorporation of iron-sulfur cluster into extramitochondrial Fe/S proteins. It is a selective cancer dependency (DepMap: 21.2% of cell lines).
Predicted to enable metal ion binding activity. Involved in iron-sulfur cluster assembly and protein maturation. Located in cytosol and nucleoplasm. Part of cytosolic [4Fe-4S] assembly targeting complex.
Source: NCBI Gene 84191 — automated summary from GO annotations (Alliance of Genome Resources).
At a glance
- Clinical variants (ClinVar): 33 total
- GTEx eGene: eQTL in 12 tissues, sQTL in 31 (q < 0.05)
- Cancer dependency (DepMap): dependent in 21.2% of screened cell lines
- Constraint (gnomAD): pLI 0.02 (LoF-tolerant), LOEUF 1.05 (unconstrained)
- MANE Select transcript:
NM_032231
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26235 |
| Approved symbol | CIAO2A |
| Name | cytosolic iron-sulfur assembly component 2A |
| Location | 15q22.31 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ22875, CIA2A |
| Ensembl gene | ENSG00000166797 |
| Ensembl biotype | protein_coding |
| OMIM | 618382 |
| Entrez | 84191 |
Gene structure
Transcript identifiers
Ensembl transcripts: 27 — 19 protein_coding, 8 nonsense_mediated_decay
MANE Select: ENST00000300030
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 3, TSL 3: 1, TSL 5: 1
ENST00000300030, ENST00000380290, ENST00000557835, ENST00000558779, ENST00000559705, ENST00000559950, ENST00000851936, ENST00000851937, ENST00000851938, ENST00000927117, ENST00000927118, ENST00000927119, ENST00000977748, ENST00000977749, ENST00000977750, ENST00000977751, ENST00000977752, ENST00000977753, ENST00001065846, ENST00001065848, ENST00001065849, ENST00001065853, ENST00001102873, ENST00001102874, ENST00001102875, ENST00001102876, ENST00001132801
RefSeq mRNA: 3 — MANE Select: NM_032231
NM_001014812, NM_001289108, NM_032231
CCDS: CCDS10189, CCDS45278
Canonical transcript exons
ENST00000300030 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001724296 | 64072565 | 64073028 |
| ENSE00001865659 | 64093645 | 64093838 |
| ENSE00003615251 | 64075492 | 64075537 |
| ENSE00003638599 | 64088687 | 64088851 |
| ENSE00003666390 | 64081102 | 64081151 |
Expression profiles
Bgee: expression breadth ubiquitous, 255 present calls, max score 99.11.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 86.1553 / max 610.0781, expressed in 1827 samples.
Highest expression (Bgee): ileal mucosa, lobe of liver, jejunal mucosa, ventricle myocardium, duodenum.
Genetic regulation across tissues (GTEx eQTL / sQTL)
CIAO2A is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 12 tissues and its splicing (sQTL) in 31 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
showing 20 of 43 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Thyroid | sqtl | 2.6e-45 | -0.95 | 15:64090212:G:A |
| Cells Cultured fibroblasts | sqtl | 9.1e-45 | -0.92 | 15:64070537:CTT:C |
| Lung | sqtl | 5.5e-28 | +0.81 | 15:64108050:C:A |
| Artery Tibial | sqtl | 1.6e-25 | -0.80 | 15:64090212:G:A |
| Adipose Subcutaneous | sqtl | 5.6e-24 | -0.74 | 15:64060835:G:T |
| Adipose Visceral Omentum | sqtl | 2.2e-23 | -0.76 | 15:64090698:C:T |
| Breast Mammary Tissue | sqtl | 3.4e-22 | +0.89 | 15:64085036:G:GAGCCAAGAATGC |
| Nerve Tibial | sqtl | 9.6e-21 | -0.72 | 15:64090212:G:A |
| Esophagus Mucosa | sqtl | 1.3e-17 | -0.75 | 15:64090830:G:A |
| Cells EBV-transformed lymphocytes | eqtl | 2.7e-17 | -0.30 | 15:64090212:G:A |
| Colon Sigmoid | sqtl | 4.7e-16 | -0.75 | 15:64090212:G:A |
| Artery Aorta | sqtl | 4.8e-16 | +0.70 | 15:64117349:A:G |
| Stomach | sqtl | 1.8e-15 | -0.78 | 15:64063083:C:G |
| Pancreas | sqtl | 5.8e-15 | -0.84 | 15:64090212:G:A |
| Esophagus Muscularis | sqtl | 7.9e-14 | -0.65 | 15:64090212:G:A |
| Adrenal Gland | sqtl | 1.5e-13 | -0.95 | 15:64090212:G:A |
| Skin Not Sun Exposed Suprapubic | sqtl | 5.0e-12 | +0.55 | 15:64105977:G:A |
| Prostate | sqtl | 5.0e-12 | +0.92 | 15:64126198:G:A |
| Colon Transverse | sqtl | 1.3e-10 | -0.55 | 15:64097544:C:T |
| Esophagus Gastroesophageal Junction | sqtl | 5.3e-10 | -0.73 | 15:64090212:G:A |
FANTOM5 promoters
3 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 150448 | 64.1973 | 1826 |
| 150449 | 15.9368 | 1784 |
| 150450 | 6.0211 | 1577 |
Top tissues by expression
showing 100 of 256 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| ileal mucosa | UBERON:0000331 | 99.11 | gold quality |
| right lobe of liver | UBERON:0001114 | 98.62 | gold quality |
| jejunal mucosa | UBERON:0000399 | 98.56 | gold quality |
| left ventricle myocardium | UBERON:0006566 | 98.50 | gold quality |
| duodenum | UBERON:0002114 | 98.12 | gold quality |
| jejunum | UBERON:0002115 | 98.07 | gold quality |
| monocyte | CL:0000576 | 98.05 | gold quality |
| kidney epithelium | UBERON:0004819 | 98.05 | gold quality |
| leukocyte | CL:0000738 | 97.97 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 97.95 | gold quality |
| right adrenal gland | UBERON:0001233 | 97.66 | gold quality |
| metanephros | UBERON:0000081 | 97.62 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 97.61 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 97.61 | gold quality |
| colonic mucosa | UBERON:0000317 | 97.60 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 97.53 | gold quality |
| liver | UBERON:0002107 | 97.52 | gold quality |
| pancreatic ductal cell | CL:0002079 | 97.48 | gold quality |
| left adrenal gland | UBERON:0001234 | 97.43 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 97.42 | gold quality |
| quadriceps femoris | UBERON:0001377 | 97.38 | gold quality |
| lymph node | UBERON:0000029 | 97.37 | gold quality |
| adrenal tissue | UBERON:0018303 | 97.37 | gold quality |
| vastus lateralis | UBERON:0001379 | 97.34 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 97.31 | gold quality |
| myocardium | UBERON:0002349 | 97.27 | gold quality |
| adrenal cortex | UBERON:0001235 | 97.22 | gold quality |
| rectum | UBERON:0001052 | 97.07 | gold quality |
| deltoid | UBERON:0001476 | 97.06 | gold quality |
| cortex of kidney | UBERON:0001225 | 97.05 | gold quality |
| tibialis anterior | UBERON:0001385 | 97.05 | gold quality |
| body of pancreas | UBERON:0001150 | 97.04 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 97.04 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 97.01 | gold quality |
| thymus | UBERON:0002370 | 96.99 | gold quality |
| metanephros cortex | UBERON:0010533 | 96.88 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 96.84 | gold quality |
| adrenal gland | UBERON:0002369 | 96.81 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 96.77 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 96.71 | gold quality |
| renal medulla | UBERON:0000362 | 96.64 | gold quality |
| amniotic fluid | UBERON:0000173 | 96.61 | gold quality |
| thyroid gland | UBERON:0002046 | 96.59 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 96.55 | gold quality |
| ventricular zone | UBERON:0003053 | 96.52 | gold quality |
| body of tongue | UBERON:0011876 | 96.51 | gold quality |
| biceps brachii | UBERON:0001507 | 96.46 | gold quality |
| pigmented layer of retina | UBERON:0001782 | 96.42 | gold quality |
| adult organism | UBERON:0007023 | 96.42 | gold quality |
| granulocyte | CL:0000094 | 96.41 | gold quality |
| spleen | UBERON:0002106 | 96.26 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 96.21 | gold quality |
| kidney | UBERON:0002113 | 96.19 | gold quality |
| placenta | UBERON:0001987 | 96.13 | gold quality |
| heart right ventricle | UBERON:0002080 | 96.08 | gold quality |
| heart left ventricle | UBERON:0002084 | 96.05 | gold quality |
| cardiac ventricle | UBERON:0002082 | 96.04 | gold quality |
| caecum | UBERON:0001153 | 95.98 | gold quality |
| skeletal muscle tissue of biceps brachii | UBERON:0004502 | 95.98 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 95.95 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 95.89 | gold quality |
| vermiform appendix | UBERON:0001154 | 95.89 | gold quality |
| bone marrow | UBERON:0002371 | 95.89 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 95.85 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 95.81 | gold quality |
| tongue | UBERON:0001723 | 95.81 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 95.81 | gold quality |
| pancreas | UBERON:0001264 | 95.80 | gold quality |
| ganglionic eminence | UBERON:0004023 | 95.77 | gold quality |
| synovial joint | UBERON:0002217 | 95.75 | gold quality |
| lower lobe of lung | UBERON:0008949 | 95.75 | gold quality |
| transverse colon | UBERON:0001157 | 95.73 | gold quality |
| muscle of leg | UBERON:0001383 | 95.69 | gold quality |
| pylorus | UBERON:0001166 | 95.63 | gold quality |
| muscle tissue | UBERON:0002385 | 95.59 | gold quality |
| oral cavity | UBERON:0000167 | 95.58 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 95.49 | gold quality |
| gastrocnemius | UBERON:0001388 | 95.43 | gold quality |
| superior surface of tongue | UBERON:0007371 | 95.42 | gold quality |
| heart | UBERON:0000948 | 95.29 | gold quality |
| gall bladder | UBERON:0002110 | 95.29 | gold quality |
| endometrium | UBERON:0001295 | 95.22 | gold quality |
| penis | UBERON:0000989 | 95.21 | gold quality |
| small intestine | UBERON:0002108 | 95.21 | gold quality |
| prostate gland | UBERON:0002367 | 95.18 | gold quality |
| tibia | UBERON:0000979 | 95.17 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 95.14 | gold quality |
| cardiac atrium | UBERON:0002081 | 95.02 | gold quality |
| right atrium auricular region | UBERON:0006631 | 94.90 | gold quality |
| spinal cord | UBERON:0002240 | 94.87 | gold quality |
| parietal pleura | UBERON:0002400 | 94.84 | gold quality |
| body of stomach | UBERON:0001161 | 94.83 | gold quality |
| intestine | UBERON:0000160 | 94.73 | gold quality |
| bronchial epithelial cell | CL:0002328 | 94.58 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 94.58 | gold quality |
| large intestine | UBERON:0000059 | 94.52 | gold quality |
| cardia of stomach | UBERON:0001162 | 94.46 | gold quality |
| apex of heart | UBERON:0002098 | 94.45 | gold quality |
| bronchus | UBERON:0002185 | 94.44 | gold quality |
| epithelium of mammary gland | UBERON:0003244 | 94.39 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-81383 | no | 283.68 |
| E-MTAB-5061 | no | 3.22 |
| E-ANND-3 | no | 0.00 |
HPA expression
RNA tissue specificity: Tissue enhanced
showing 60 of 80 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Liver | tissue | 245.2 | low |
| Skeletal muscle | tissue | 117.7 | medium |
| Duodenum | tissue | 101.4 | medium |
| Lymph node | tissue | 98.3 | not detected |
| Tongue | tissue | 90.9 | |
| Small intestine | tissue | 81.7 | medium |
| Colon | tissue | 77.5 | medium |
| Kidney | tissue | 75.8 | medium |
| Thyroid gland | tissue | 75.0 | medium |
| Heart muscle | tissue | 73.0 | low |
| Parathyroid gland | tissue | 70.8 | medium |
| Bone marrow | tissue | 66.7 | not detected |
| Stomach 1 | tissue | 64.8 | high |
| Rectum | tissue | 64.2 | medium |
| Tonsil | tissue | 62.6 | not detected |
| Placenta | tissue | 61.5 | medium |
| Corpus callosum | tissue | 60.9 | |
| Choroid plexus | tissue | 57.3 | |
| Pancreas | tissue | 56.3 | medium |
| Thymus | tissue | 56.2 | |
| Adrenal gland | tissue | 55.2 | medium |
| Appendix | tissue | 50.6 | medium |
| Spinal cord | tissue | 49.9 | |
| Spleen | tissue | 49.7 | not detected |
| Midbrain | tissue | 47.0 | |
| Medulla oblongata | tissue | 46.4 | |
| Thalamus | tissue | 46.2 | |
| Breast | tissue | 45.4 | medium |
| Pons | tissue | 44.3 | |
| Substantia nigra | tissue | 44.2 | |
| Urinary bladder | tissue | 43.3 | low |
| Putamen | tissue | 41.7 | |
| Salivary gland | tissue | 41.4 | medium |
| Lung | tissue | 40.9 | medium |
| Superior colliculi | tissue | 40.8 | |
| Gallbladder | tissue | 40.3 | medium |
| Epididymis | tissue | 38.8 | low |
| Periaqueductal gray | tissue | 38.2 | |
| Caudate putamen | tissue | 37.6 | |
| Prostate | tissue | 36.7 | not detected |
| Frontal cortex | tissue | 35.9 | |
| Septum | tissue | 35.0 | |
| Ventral forebrain | tissue | 34.9 | |
| Hypothalamus | tissue | 34.3 | |
| Hippocampal formation | tissue | 30.4 | |
| Fallopian tube | tissue | 30.2 | medium |
| Cervix | tissue | 29.6 | medium |
| Basal ganglia | tissue | 28.5 | low |
| Esophagus | tissue | 28.0 | low |
| Cerebral cortex | tissue | 27.2 | medium |
| Somatosensory cortex | tissue | 27.2 | |
| Motor cortex | tissue | 27.1 | |
| Ovary | tissue | 26.8 | not detected |
| Occipital cortex | tissue | 26.6 | |
| Adipose tissue | tissue | 26.1 | low |
| Amygdala | tissue | 26.1 | |
| Pituitary gland | tissue | 26.0 | |
| Seminal vesicle | tissue | 25.3 | low |
| Retrosplenial cortex | tissue | 24.4 | |
| Olfactory bulb | tissue | 24.3 |
Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — White matter (60.9), Ventral spinal cord (49.9), Dorsal spinal cord (44.8), Corpus callosum, splenium (white matter) (40.8), Lateral funiculus (white matter) (37.3).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting CIAO2A by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 42 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-LET-7A-3P | 100.00 | 74.03 | 3932 |
| HSA-LET-7B-3P | 100.00 | 74.08 | 3913 |
| HSA-LET-7F-1-3P | 100.00 | 74.02 | 3928 |
| HSA-MIR-98-3P | 100.00 | 74.08 | 3907 |
| HSA-MIR-3120-5P | 100.00 | 65.56 | 965 |
| HSA-MIR-4500 | 99.99 | 72.72 | 2367 |
| HSA-MIR-520D-5P | 99.98 | 73.34 | 4883 |
| HSA-MIR-524-5P | 99.98 | 73.43 | 4882 |
| HSA-MIR-5696 | 99.98 | 72.36 | 4487 |
| HSA-MIR-6888-3P | 99.97 | 65.95 | 1170 |
| HSA-MIR-4666A-3P | 99.96 | 71.71 | 3434 |
| HSA-MIR-381-3P | 99.93 | 71.87 | 2854 |
| HSA-MIR-6508-5P | 99.92 | 70.67 | 2465 |
| HSA-MIR-300 | 99.92 | 71.76 | 2856 |
| HSA-MIR-7-1-3P | 99.91 | 71.53 | 4384 |
| HSA-MIR-7-2-3P | 99.91 | 71.40 | 4394 |
| HSA-MIR-7162-3P | 99.89 | 68.16 | 1682 |
| HSA-MIR-8067 | 99.86 | 69.59 | 2260 |
| HSA-MIR-1200 | 99.71 | 70.42 | 1838 |
| HSA-MIR-4251 | 99.40 | 69.19 | 3363 |
| HSA-MIR-4797-5P | 99.39 | 68.01 | 1354 |
| HSA-MIR-2115-3P | 99.31 | 69.68 | 2026 |
| HSA-MIR-6719-3P | 99.29 | 67.78 | 1387 |
| HSA-MIR-580-5P | 99.28 | 70.94 | 1776 |
| HSA-MIR-593-3P | 99.22 | 67.28 | 1327 |
| HSA-MIR-544B | 99.18 | 67.41 | 1632 |
| HSA-MIR-4324 | 99.04 | 70.14 | 1569 |
| HSA-MIR-4711-5P | 98.89 | 68.00 | 965 |
| HSA-MIR-760 | 98.81 | 66.65 | 1392 |
| HSA-MIR-501-5P | 98.77 | 68.88 | 1328 |
Functional genomics
gnomAD constraint: pLI 0.0232, LOEUF 1.05, missense Z 0.127 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000300030 — one region, missense o/e 1.00.
DepMap (CRISPR cell-line fitness): dependent in 21.2% of screened cell lines.
Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): NCI-H1573 (-1.399), HCC-33 (-1.31), LN-340 (-1.148), HT-144_DAB_R (-1.123), JVE-015 (-1.065), SNU-620 (-1.05), SNU-1544 (-1.043), HT-144_DAB_ROX_R (-1.04), SUM-149PT (-1.03), KKU-100 (-1.021), HuNS1 (-1.016), Mero-14 (-1.01), JHUEM-1 (-1.004), C84 (-1.002), MUTZ-8 (-0.958).
Literature-anchored findings (GeneRIF, showing 5)
- putative metal-binding site of bacterial DUF59 proteins is not conserved in Fam96a, but Fam96a interacts tightly in vitro with Ciao1, the cytosolic iron-assembly protein (PMID:22683786)
- CIA2B-CIA1-MMS19 and CIA2A-CIA1 assist different branches of Fe/S protein assembly and intimately link this process to cellular iron regulation via IRP1 Fe/S cluster maturation and IRP2 stabilization. (PMID:23891004)
- FAM96A expression was much reduced in tumorigenic ICC-SCs. (PMID:25716227)
- our data suggest that hTERTR-FAM96A may serve as an efficient anti-tumor agent for the treatment of hepatocellular carcinoma. (PMID:28443470)
- FAM96A suppresses epithelial-mesenchymal transition and tumor metastasis by inhibiting TGFbeta1 signals. (PMID:35513087)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | ciao2a | ENSDARG00000104940 |
| mus_musculus | Ciao2a | ENSMUSG00000032381 |
| rattus_norvegicus | Ciao2a | ENSRNOG00000017119 |
| drosophila_melanogaster | galla-1 | FBGN0034543 |
Paralogs (1): CIAO2B (ENSG00000166595)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1915500) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 1 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| decreased erythrocyte cell number | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Bos taurus | Q3T0U7 | 96.9% | Diamond |
| Schizosaccharomyces pombe 972h- | Q9UTL0 | 61.2% | Diamond |
| Dictyostelium discoideum | Q54QK1 | 60.9% | Diamond |
| Arabidopsis thaliana | Q9C9G6 | 60.5% | Diamond |
| Caenorhabditis elegans | O62252 | 60.3% | Diamond |
| Saccharomyces cerevisiae S288C | P38829 | 55.5% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| DAPK2 | protein-coding | 23604 |
| MIR422A | ncRNA | 494334 |
| SNX1 | protein-coding | 6642 |
| HERC1 | protein-coding | 8925 |
| CSNK1G1 | protein-coding | 53944 |
| PPIB | protein-coding | 5479 |
| SNX22 | protein-coding | 79856 |
| USP3-AS1 | ncRNA | 100130855 |
| FBXL22 | protein-coding | 283807 |
| PCLAF | protein-coding | 9768 |
Protein
Protein identifiers
Cytosolic iron-sulfur assembly component 2A — Q9H5X1 (reviewed: Q9H5X1)
Alternative names: MIP18 family protein FAM96A
All UniProt accessions (4): Q9H5X1, A0AAQ5BII0, H0YKV4, H0YLH6
UniProt curated annotations — full annotation on UniProt →
Function. Component of the cytosolic iron-sulfur protein assembly (CIA) complex, a multiprotein complex that mediates the incorporation of iron-sulfur cluster into extramitochondrial Fe/S proteins. As a CIA complex component and in collaboration with CIAO1 specifically matures ACO1 and stabilizes IREB2, connecting cytosolic iron-sulfur protein maturation with cellular iron regulation. May play a role in chromosome segregation through establishment of sister chromatid cohesion. May induce apoptosis in collaboration with APAF1.
Subunit / interactions. Monomer and homodimer. Component of the CIA complex. Interacts with CIAO1. Interacts with IREB2. Interacts with APAF1.
Subcellular location. Cytoplasm.
Tissue specificity. Substantially enriched in macrophages.
Similarity. Belongs to the MIP18 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q9H5X1-1 | 1 | yes |
| Q9H5X1-2 | 2 |
RefSeq proteins (3): NP_001014812, NP_001276037, NP_115607* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002744 | MIP18-like | Domain |
| IPR034904 | FSCA_dom_sf | Homologous_superfamily |
| IPR039796 | MIP18 | Family |
Pfam: PF01883
UniProt features (23 total): binding site 8, helix 6, strand 6, chain 1, turn 1, splice variant 1
Structure
Experimental structures (PDB)
3 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 3UX2 | Crystal Structure of Domain-Swapped Fam96a Major dimer | X-RAY DIFFRACTION | 1.8 |
| 3UX3 | Crystal Structure of Domain-Swapped Fam96a minor dimer | X-RAY DIFFRACTION | 1.8 |
| 2M5H | NMR structure note: solution structure of monomeric human FAM96A | SOLUTION NMR |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9H5X1-F1 | 86.90 | 0.69 |
Human Protein Atlas
Protein class: Predicted intracellular proteins
Protein evidence: Evidence at protein level
Subcellular location (HPA, imaging): cytosol; nucleoplasm
Antibody reliability (HPA): IH approved · IF enhanced
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (8)
| Position | Role |
|---|---|
| 89 | Zn(2+) |
| 123 | Zn(2+) |
| 150 | Zn(2+) |
| 153 | Zn(2+) |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
MSigDB gene sets: 163 (showing top):
MODULE_151, CHIANG_LIVER_CANCER_SUBCLASS_UNANNOTATED_DN, TGACCTY_ERR1_Q2, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_PROTEIN_MATURATION, GATA6_01, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, DODD_NASOPHARYNGEAL_CARCINOMA_UP, RYTTCCTG_ETS2_B, MODULE_568, MODULE_491, MODULE_114, AACATTC_MIR4093P, GOBP_CELL_CYCLE_PROCESS
GO Biological Process (3): chromosome segregation (GO:0007059), iron-sulfur cluster assembly (GO:0016226), protein maturation (GO:0051604)
GO Molecular Function (2): metal ion binding (GO:0046872), protein binding (GO:0005515)
GO Cellular Component (4): nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), cytosolic [4Fe-4S] assembly targeting complex (GO:0097361)
GO top-level categories
12 GO namespaces:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| cell cycle process | 1 |
| metallo-sulfur cluster assembly | 1 |
| gene expression | 1 |
| protein metabolic process | 1 |
| cation binding | 1 |
| binding | 1 |
| nuclear lumen | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
| intracellular protein-containing complex | 1 |
| iron-sulfur cluster assembly complex | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 5 of 9 annotations. The rest are phylogenetic / computational / electronic (IEA).
5 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| iron-sulfur cluster assembly | BP | direct assay |
| protein maturation | BP | mutant phenotype |
| cytosol | CC | direct assay |
| cytosolic [4Fe-4S] assembly targeting complex | CC | direct assay |
| nucleoplasm | CC | direct assay |
Protein interactions and networks
STRING
showing 15 of 622 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CIAO2A | CIAO1 | O76071 | 783 |
| CIAO2A | MMS19 | Q96T76 | 717 |
| CIAO2A | CIAO3 | Q9H6Q4 | 656 |
| CIAO2A | NUBP1 | P53384 | 605 |
| CIAO2A | CIAPIN1 | Q6FI81 | 572 |
| CIAO2A | ABCB7 | O75027 | 516 |
| CIAO2A | GLRX3 | O76003 | 504 |
| CIAO2A | QNG1 | Q5T6V5 | 481 |
| CIAO2A | ISCA1 | Q9BUE6 | 466 |
| CIAO2A | CYB561 | P49447 | 461 |
| CIAO2A | FBXL5 | Q9UKA1 | 453 |
| CIAO2A | IREB2 | P48200 | 430 |
| CIAO2A | NDOR1 | Q9UHB4 | 426 |
| CIAO2A | SLC25A28 | Q96A46 | 407 |
| CIAO2A | SLC25A37 | Q9NYZ2 | 405 |
IntAct
Human interaction partners of CIAO2A in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
25 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| CIAO1 | physical association | 0.950 | 17 |
| TMED8 | physical association | 0.560 | 6 |
| CREB3L1 | physical association | 0.560 | 5 |
| APOA2 | physical association | 0.560 | 3 |
| CMTM6 | physical association | 0.560 | 3 |
| DERL1 | physical association | 0.560 | 3 |
| DGAT2L6 | physical association | 0.560 | 3 |
| EBAG9 | physical association | 0.560 | 3 |
| ERGIC3 | physical association | 0.560 | 3 |
| FKBP7 | physical association | 0.560 | 3 |
| GJA8 | physical association | 0.560 | 3 |
| GSC2 | physical association | 0.560 | 3 |
| KCNIP1 | physical association | 0.560 | 3 |
| LIME1 | physical association | 0.560 | 3 |
| MEST | physical association | 0.560 | 3 |
| PLP2 | physical association | 0.560 | 3 |
| PLPP6 | physical association | 0.560 | 3 |
| PLPPR2 | physical association | 0.560 | 3 |
| PRAF2 | physical association | 0.560 | 3 |
| RHBDD2 | physical association | 0.560 | 3 |
| SETD4 | physical association | 0.560 | 3 |
| SIN3A | physical association | 0.560 | 3 |
| TNFRSF10D | physical association | 0.560 | 3 |
| VAMP3 | physical association | 0.560 | 3 |
| MAP2K7 | association | 0.350 | 1 |
SIGNOR signaling
1 signaling interactions:
| A | Effect | B | Mechanism |
|---|---|---|---|
| CIAO2A | “form complex” | “CIAO1-CIAO2A-CIAO3 cytosolic iron-sulfur protein assembly complex” | binding |
Disease & clinical
Genetic variants
Variant evidence for CIAO2A: 33 ClinVar records (0 pathogenic / likely pathogenic).
ClinVar
33 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 25 |
| Likely benign | 0 |
| Benign | 0 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 36 predictions of 340):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 15:64075545 | acceptor_gain | 1.0000 | |
| 15:64088685–64088686 | donor_loss | 1.0000 | 5 |
| 15:64093643–64093644 | donor_loss | 1.0000 | 4 |
| 15:64073029–64073030 | acceptor_loss | 0.9900 | 6 |
| 15:64075538–64075539 | acceptor_loss | 0.9900 | 5 |
| 15:64088852–64088853 | acceptor_gain | 0.9900 | 6 |
| 15:64093644 | donor_loss | 0.9900 | |
| 15:64093663 | donor_gain | 0.9900 | |
| 15:64073036 | acceptor_loss | 0.9800 | |
| 15:64075490–64075491 | donor_loss | 0.9800 | 6 |
AlphaMissense
507 missense substitutions predicted likely pathogenic (of 1,027 scored), across 108 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D135 | 8 | 1.000 | 1.000 |
| D49 | 8 | 0.998 | 1.000 |
| H123 | 8 | 0.995 | 0.999 |
| N145 | 8 | 0.979 | 0.997 |
| F83 | 8 | 0.954 | 0.999 |
| H89 | 8 | 0.947 | 0.992 |
| D42 | 8 | 0.891 | 0.967 |
| D128 | 8 | 0.831 | 0.982 |
| C90 | 7 | 0.999 | 1.000 |
| E137 | 7 | 0.998 | 0.999 |
| E51 | 7 | 0.994 | 0.998 |
| E144 | 7 | 0.990 | 0.998 |
| Q132 | 7 | 0.987 | 0.999 |
| N134 | 7 | 0.976 | 0.996 |
| K136 | 7 | 0.972 | 1.000 |
| C155 | 7 | 0.964 | 0.997 |
| I96 | 7 | 0.949 | 0.999 |
| N130 | 7 | 0.942 | 0.997 |
| C99 | 7 | 0.929 | 0.999 |
| E57 | 7 | 0.887 | 0.987 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
2 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Kidney Renal Clear Cell Carcinoma (TCGA) | favorable | 1.59e-06 |
| Prostate Adenocarcinoma (TCGA) | unfavorable | 0.000925 |
Disease associations
OMIM: gene MIM:618382 | disease phenotypes:
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL4295943 (SINGLE PROTEIN)
PharmGKB: 1 entry (CPIC guideline: no)
CTD chemical–gene interactions
29 total (human), top 29 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, affects cotreatment, increases abundance, increases expression | 3 |
| Cadmium | decreases expression | 2 |
| Cyclosporine | decreases expression | 2 |
| perfluorodecanesulfonic acid | increases expression | 1 |
| dicrotophos | decreases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| bisphenol A | increases expression | 1 |
| arsenite | affects binding, increases reaction | 1 |
| perfluorooctanoic acid | increases expression | 1 |
| manganese chloride | increases expression, affects cotreatment, increases abundance | 1 |
| perfluorooctane sulfonic acid | increases expression | 1 |
| K 7174 | decreases expression | 1 |
| perfluorobutanesulfonic acid | increases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Antimycin A | decreases expression | 1 |
| Arsenic | increases abundance, increases expression, affects cotreatment | 1 |
| Cisplatin | increases expression | 1 |
| Dichlorodiphenyl Dichloroethylene | increases expression | 1 |
| Doxorubicin | increases expression | 1 |
| Ivermectin | decreases expression | 1 |
| Manganese | increases abundance, increases expression, affects cotreatment | 1 |
| Rotenone | decreases expression | 1 |
| Urethane | decreases expression | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
| Antirheumatic Agents | decreases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
| Copper Sulfate | decreases expression | 1 |
| Particulate Matter | decreases expression, increases abundance | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL4118609 | Binding | Binding affinity to FAM96A in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay | Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — *Bioorg Med Chem* |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.